摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

ethyl(1-azabicyclo[2.2.2]octan-3-ylidene)cyanoacetate | 141593-49-9

中文名称
——
中文别名
——
英文名称
ethyl(1-azabicyclo[2.2.2]octan-3-ylidene)cyanoacetate
英文别名
Ethyl (1-azabicyclo[2.2.2]octan-3-ylidene)cyanoacetate;ethyl 2-(1-azabicyclo[2.2.2]octan-3-ylidene)-2-cyanoacetate
ethyl(1-azabicyclo[2.2.2]octan-3-ylidene)cyanoacetate化学式
CAS
141593-49-9
化学式
C12H16N2O2
mdl
——
分子量
220.271
InChiKey
WRCZZMYKSMOYBK-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.6
  • 重原子数:
    16
  • 可旋转键数:
    3
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.67
  • 拓扑面积:
    53.3
  • 氢给体数:
    0
  • 氢受体数:
    4

反应信息

  • 作为反应物:
    描述:
    ethyl(1-azabicyclo[2.2.2]octan-3-ylidene)cyanoacetate 在 palladium on activated charcoal 氢气 作用下, 以 乙醇 为溶剂, 生成 ethyl (1-azabicyclo[2.2.2]octan-3-yl)cyanoacetate
    参考文献:
    名称:
    Muscarinic Analgesics with Potent and Selective Effects on the Gastrointestinal Tract:  Potential Application for the Treatment of Irritable Bowel Syndrome
    摘要:
    Irritable bowel syndrome (IBS) is a pathopysiolocal condition characterized by abnormal bowel habits that are frequently accompanied by abdominal pain. Current therapy based on reducing high-amplitude GI contractions with nonselective muscarinic antagonists is limited in efficacy due to typical muscarinic side effects and provides no pain relief. We have previously found potent antinociceptive agents acting through muscarinic receptors. In the present work, new 1,2,5-thiadiazole-based structures with muscarinic activity have been evaluated both for activity as analgesics in the mouse withing assay and for activity in normalizing spontaneous cluster contractions in ferret jejunum as a model of IBS in humans. (5R,6R)-exo-6-[4-[(4,4,4-Trifluorobutyl)thio]-1,2,5-thiadiazol-3-yl]-1-azabicyclo[3.2.1]octane (35, LY316108/NNC11-2192) was found to offer an exceptional profile combining analgesic potency in mouse writhing (ED(50) = 0.1 mg/kg) along with potency for normalization of GI motility (ED(50) = 0.17 mg/kg). This combination of GI and analgesic potency suggests 35 as an excellent candidate for evaluation as a potential treatment of IBS.
    DOI:
    10.1021/jm9602470
  • 作为产物:
    参考文献:
    名称:
    Muscarinic Analgesics with Potent and Selective Effects on the Gastrointestinal Tract:  Potential Application for the Treatment of Irritable Bowel Syndrome
    摘要:
    Irritable bowel syndrome (IBS) is a pathopysiolocal condition characterized by abnormal bowel habits that are frequently accompanied by abdominal pain. Current therapy based on reducing high-amplitude GI contractions with nonselective muscarinic antagonists is limited in efficacy due to typical muscarinic side effects and provides no pain relief. We have previously found potent antinociceptive agents acting through muscarinic receptors. In the present work, new 1,2,5-thiadiazole-based structures with muscarinic activity have been evaluated both for activity as analgesics in the mouse withing assay and for activity in normalizing spontaneous cluster contractions in ferret jejunum as a model of IBS in humans. (5R,6R)-exo-6-[4-[(4,4,4-Trifluorobutyl)thio]-1,2,5-thiadiazol-3-yl]-1-azabicyclo[3.2.1]octane (35, LY316108/NNC11-2192) was found to offer an exceptional profile combining analgesic potency in mouse writhing (ED(50) = 0.1 mg/kg) along with potency for normalization of GI motility (ED(50) = 0.17 mg/kg). This combination of GI and analgesic potency suggests 35 as an excellent candidate for evaluation as a potential treatment of IBS.
    DOI:
    10.1021/jm9602470
点击查看最新优质反应信息

文献信息

  • Method of treating urinary bladder dysfunctions
    申请人:Novo Nordisk A/S
    公开号:US05612351A1
    公开(公告)日:1997-03-18
    The present invention relates to a novel method for treating a mammal suffering from urinary bladder dysfunctions.
    这项发明涉及一种治疗患有尿道膀胱功能障碍的哺乳动物的新方法。
  • Central Cholinergic Agents. III. Synthesis of 2-Alkoxy-2,8-diazaspiro(4.5)decane-1,3-diones as Muscarinic Agonists.
    作者:Yuji ISHIHARA、Hidehumi YUKIMASA、Masaomi MIYAMOTO、Giichi GOTO
    DOI:10.1248/cpb.40.1177
    日期:——
    and tested for muscarinic receptor binding affinity using [3H]pirenzepine and [3H]oxotremorine M as ligands. They were also evaluated for agonistic activities in the guinea pig ileum assay. 2-Methoxy- 2,8-diazaspiro[4.5]decane-1,3-dione (1i) was found to be a relatively M1 selective agonist. It reversed CO2-induced impairment of passive avoidance response with long duration of action, but also displayed
    合成了一系列的2-烷基-2,8-二氮杂螺[4.5]癸烷-1,3-二和相关化合物,并以[3H]哌仑西平和[3H]苯甲酸M作为配体测试了毒蕈碱受体的结合亲和力。还通过豚鼠回肠试验评估了它们的激动活性。发现2-甲基-2,8-二氮杂螺[4.5]癸烷-1,3-二(1i)是相对M1选择性的激动剂。它以较长的作用时间逆转了CO2引起的被动回避反应的损害,但在低剂量时也表现出外周效应。为了最小化这些副作用,我们提出了将1i与毒蕈碱拮抗剂结合的想法。因此,检查了1i的氨基甲酸连接的共轭物(1u)与甲基托品
  • Heterocyclic compounds and their preparation and use
    申请人:Novo Nordisk A.S
    公开号:US05641791A1
    公开(公告)日:1997-06-24
    The present invention relates to therapeutically active azabicyclic compounds, a method of preparing the same and to pharmaceutical compositions comprising the compounds. The novel compounds are useful as stimulants of the cognitive function of the forebrain and hippocampus of mammals and especially in the treatment of Alzheimer's disease, severe painful conditions and glaucoma.
    本发明涉及治疗活性的杂环化合物、其制备方法以及包含该化合物的制药组合物。这些新型化合物可用作哺乳动物前脑和海马的认知功能的刺激剂,特别适用于治疗阿尔茨海默病、严重疼痛症和青光眼。
  • Antipsychotic method
    申请人:——
    公开号:US05663182A1
    公开(公告)日:1997-09-02
    The present invention relates to a novel method for treating a mammal suffering from or susceptible to schizophrenia and schizophreniform diseases.
    本发明涉及一种治疗患有或易患精神分裂症和分裂样疾病哺乳动物的新方法。
  • Certain 3-(1,2,5-oxa- or thiadiazol-4-yl)-1-azabicyclo [2.2.2]octanes
    申请人:Novo Nordisk A/S
    公开号:US05260314A1
    公开(公告)日:1993-11-09
    The present invention relates to therapeutically active piperidine compounds, a method of preparing the same and to pharmaceutical compositions comprising the compounds. The novel compounds are useful as stimulants of the cognitive function of the forebrain and hippocampus of mammals and especially in the treatment of Alzheimer's disease, severe painful conditions and glaucoma.
    本发明涉及有治疗活性的吡啶化合物,其制备方法以及包含这些化合物的制药组合物。这些新型化合物可用作哺乳动物的前脑和海马的认知功能的刺激剂,特别是用于治疗阿尔茨海默病、严重疼痛和青光眼。
查看更多

同类化合物

阿地溴铵中间体 阿地溴铵 阿地溴胺杂质10 螺[1-氮杂双环[2.2.2]辛烷-3,2’-环氧乙烷] 盐酸盐 螺[1-氮杂双环[2.2.2]辛烷-3,2'-环氧乙烷] 苯环喹溴铵 羟甲基-7-氨基头孢烷酸 羟奎溴铵 索非那新杂质K 盐酸戊乙奎醚 沙可美林 帕洛诺司琼杂质23 奎宁环盐酸盐 奎宁环-4-基甲胺二盐酸盐 奎宁环-3-醇 盐酸盐 奎宁环-3-醇 奎宁环-3-硫醇 奎宁环-3-甲腈 奎宁环-2-酮肟 奎宁环-2-胺 奎宁环 化合物IBIGLUSTAT 化合物 T30247 克利溴铵杂质A 二盐酸(+)-N-(1(S)-苯基乙基)-1-氮杂二环[2.2.2]辛烷-3(R)-胺 二环[3.1.0]己烷-2,6-二羧酸,2-氨基-3-氟-,(1R,2R,3R,5S,6R)-rel- 乙酰克里定 a-(羟基甲基)-苯乙酸1-氮杂双环[2.2.2]辛-3-基酯 [(2S,5R)-5-乙烯基-1-氮杂双环[2.2.2]辛-2-基]甲醇 [(2E)-2-(1-铵双环[2.2.2]辛烷-3-亚基)乙基]2-环戊基-2-羟基-2-苯基乙酸酯氯化物 S-3-氨基奎宁环胺盐酸盐 S-3-氨基奎宁环二盐酸盐 R-3-氨基奎宁环二盐酸盐 O-吡喃鼠李糖基-(1-3)-O-吡喃木糖基-(1-2)-O-吡喃鼠李糖基-(1-4)-O-吡喃葡萄糖基-(1-1)-2-N-二十四烷酰(神经)鞘氨醇 N-苄基-1-氮杂双环[2.2.2]-3-辛胺 N-羟基奎宁环-3-羧酰胺 N-甲基醋克利定碘化物 N-甲基-1-氮杂二环[2.2.2]辛烷-3-胺 8-(1-甲基吡咯烷-2-基)-1-氮杂双环[2.2.2]辛烷 7-甲基-1-氮杂双环[2.2.2]辛烷-8-醇 5H-1,3-二噁唑并[4,5-c]吡咯-5-羧酸,4-[[[(1,1-二甲基乙基)二甲基甲硅烷基]氧代]甲基]四氢-2,2-二甲基-6-[4-(苯基甲氧基)-5-[[2-(三甲基甲硅烷基)乙氧基]甲基]-5H-吡咯并[3,2-d]嘧啶-7-基]-,1,1-二甲基乙基酯,(3aR,4R,6S,6aS)- 5-乙烯基-1-氮杂双环[2.2.2]辛烷-2-甲醛 4-碘-1-氮杂双环(2.2.2)辛烷 4-甲基-1-氮杂双环[2.2.2]辛烷 4-溴-1-氮杂双环[2.2.2]辛烷 4-氰奎宁环 4-氨甲基奎宁环 4-氟奎宁环-3-酮 4-奎宁环甲醛 4-乙基-1-氮杂双环[2.2.2]辛烷